B. Riley Securities Maintains Buy on Unicycive Therapeutics, Maintains $22 Price Target
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
B. Riley Securities analyst Mayank Mamtani maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $22 price target.
B. Riley Securities analyst Mayank Mamtani maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $22 price target.